$159 Million is the total value of Prosight Management, LP's 32 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 75.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHPG | New | SHIRE PLCsponsored adr | $21,828,000 | – | 146,114 | +100.0% | 13.69% | – |
| AGN | Sell | ALLERGAN PLC | $15,954,000 | -0.5% | 94,800 | -3.3% | 10.01% | -15.1% |
| MGNX | Sell | MACROGENICS INC | $11,196,000 | -3.0% | 445,000 | -26.8% | 7.02% | -17.3% |
| SBRA | Buy | SABRA HEALTH CARE REIT INC | $10,237,000 | +35.6% | 580,000 | +44.3% | 6.42% | +15.7% |
| AKAOQ | Buy | ACHAOGEN INC | $8,561,000 | +39.6% | 661,054 | +15.8% | 5.37% | +19.0% |
| TLGT | New | TELIGENT INC NEW | $8,308,000 | – | 2,472,561 | +100.0% | 5.21% | – |
| AFAM | Buy | ALMOST FAMILY INC | $7,560,000 | +50.8% | 135,000 | +49.1% | 4.74% | +28.6% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $6,107,000 | +24.7% | 297,750 | +72.2% | 3.83% | +6.4% |
| CI | New | CIGNA CORPORATION | $5,401,000 | – | 32,200 | +100.0% | 3.39% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $5,255,000 | – | 2,538,525 | +100.0% | 3.30% | – |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $5,229,000 | -44.8% | 530,848 | -21.8% | 3.28% | -52.9% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $5,140,000 | – | 63,400 | +100.0% | 3.22% | – |
| DXCM | Buy | DEXCOM INC | $4,820,000 | +169.3% | 65,000 | +108.3% | 3.02% | +129.7% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $4,756,000 | – | 120,400 | +100.0% | 2.98% | – |
| CDTX | Sell | CIDARA THERAPEUTICS INC | $4,746,000 | -57.6% | 1,186,355 | -28.0% | 2.98% | -63.9% |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $3,845,000 | – | 563,763 | +100.0% | 2.41% | – |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $3,546,000 | -12.6% | 209,842 | -58.6% | 2.22% | -25.4% |
| New | INOGEN INCput | $3,292,000 | – | 26,800 | +100.0% | 2.06% | – | |
| QTNT | Sell | QUOTIENT LTD | $3,213,000 | -30.4% | 682,180 | -26.8% | 2.02% | -40.6% |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $3,026,000 | +2.5% | 1,043,550 | -1.3% | 1.90% | -12.5% |
| New | CLOVIS ONCOLOGY INCcall | $2,640,000 | – | 50,000 | +100.0% | 1.66% | – | |
| CIVI | New | CIVITAS SOLUTIONS INC | $2,532,000 | – | 164,396 | +100.0% | 1.59% | – |
| CNC | Sell | CENTENE CORP DEL | $2,498,000 | -65.1% | 23,375 | -67.1% | 1.57% | -70.2% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $2,429,000 | -10.7% | 46,001 | +15.0% | 1.52% | -23.8% |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $1,933,000 | -39.5% | 148,682 | -16.7% | 1.21% | -48.4% |
| KND | New | KINDRED HEALTHCARE INC | $1,485,000 | – | 162,326 | +100.0% | 0.93% | – |
| Sell | NABRIVA THERAPEUTICS PLC | $1,221,000 | -58.5% | 242,689 | -50.6% | 0.77% | -64.6% | |
| NVLNF | Sell | NOVELION THERAPEUTICS INC | $816,000 | -11.8% | 233,003 | -21.4% | 0.51% | -24.7% |
| QURE | Sell | UNIQURE NV | $801,000 | -85.6% | 34,100 | -88.0% | 0.50% | -87.8% |
| BLCM | Sell | BELLICUM PHARMACEUTICALS INC | $696,000 | -72.5% | 106,050 | -64.8% | 0.44% | -76.6% |
| AMPE | New | AMPIO PHARMACEUTICALS INC | $378,000 | – | 111,150 | +100.0% | 0.24% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -12,000 | -100.0% | -0.30% | – |
| ACHC | Exit | ACADIA HEALTHCARE COMPANY IN | $0 | – | -26,916 | -100.0% | -0.65% | – |
| CFMS | Exit | CONFORMIS INC | $0 | – | -400,000 | -100.0% | -0.70% | – |
| LPCN | Exit | LIPOCINE INC NEW | $0 | – | -373,101 | -100.0% | -0.94% | – |
| Exit | ON ASSIGNMENT INCput | $0 | – | -25,700 | -100.0% | -1.22% | – | |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -44,600 | -100.0% | -1.52% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -110,000 | -100.0% | -2.57% | – |
| ELGX | Exit | ENDOLOGIX INC | $0 | – | -655,815 | -100.0% | -2.58% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -171,352 | -100.0% | -3.36% | – |
| CMRX | Exit | CHIMERIX INC | $0 | – | -1,478,519 | -100.0% | -5.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.